Travel Medicine and Infectious Disease最新文献

{"title":"Hantavirus and Leptospira are important causes of nonspecific acute febrile syndrome, Meta, Colombia","authors":"Liliana Sánchez-Lerma ,&nbsp;Salim Mattar ,&nbsp;Verónica Contreras ,&nbsp;Jorge Miranda ,&nbsp;Vaneza Tique ,&nbsp;Virginia Rodríguez ,&nbsp;Derly Rodriguez ,&nbsp;Sonia Lopez ,&nbsp;Andrés Rojas-Gulloso","doi":"10.1016/j.tmaid.2025.102800","DOIUrl":"10.1016/j.tmaid.2025.102800","url":null,"abstract":"<div><h3>Introduction</h3><div>Acute undifferentiated febrile illnesses are fevers lasting less than fourteen days without an evident focus of infection on the initial physical examination or with inconclusive laboratory tests.</div></div><div><h3>Objective</h3><div>Carry out epidemiological surveillance of the etiology of acute undifferentiated febrile syndrome in the Meta department.</div></div><div><h3>Methods</h3><div>A descriptive, prospective cross-sectional study was carried out between February 2021 and June 2023 in a first-level hospital in the department of Meta, Colombia. All enrolled patients underwent routine hematology and blood biochemistry examinations. RT-qPCR was performed for Dengue and serology for laboratory diagnoses using ELISA and MAT for Hantavirus and Leptospirosis, respectively. A descriptive and bivariate analysis was performed using SPSS vr 23.0.</div></div><div><h3>Results</h3><div>Of the study's total of one hundred patients, 14 % showed antibodies against hantavirus IgG, of which two were seroconverted. In addition, a risk factor OR = 8.3 (CI = 1.8–38.4) for Hantavirus was found in those patients who had contact with farm animals. Regarding leptospirosis, 3 % of the sera agglutinated with titers greater than 1:400, resulting in a primary infection; 11 % of the sera presented agglutination with titers no greater than 1:200 as exposure to leptospirosis. The bivariate analysis showed an OR = 2.4; CI = 0.75–7.4 with water recreational activities in the last 30 days before the onset of symptoms.</div></div><div><h3>Conclusions</h3><div>Our study demonstrates the importance of Hantavirus, Dengue, and leptospirosis as a cause of acute undifferentiated febrile illnesses. Coinfections are frequent in one of the tropical areas of Colombia, so it is crucial to establish a more precise diagnosis.</div></div>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"64 ","pages":"Article 102800"},"PeriodicalIF":6.3,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aedes-borne arboviral human infections in Europe from 2000 to 2023: A systematic review and meta-analysis","authors":"Nadja Hedrich ,&nbsp;Maria Bekker-Nielsen Dunbar ,&nbsp;Martin P. Grobusch ,&nbsp;Patricia Schlagenhauf","doi":"10.1016/j.tmaid.2025.102799","DOIUrl":"10.1016/j.tmaid.2025.102799","url":null,"abstract":"<div><h3>Introduction</h3><div>Aedes-borne arboviral infections, both imported and autochthonous, are reported in Europe. We evaluated the landscape of these infections in Europe over 23 years and attempted to pre-empt the trajectory of impact of these infections in the climatic context of <em>Aedes</em> mosquito expansion in Europe.</div></div><div><h3>Methods</h3><div>This <strong>systematic review</strong> was conducted in accordance with PRISMA guidelines and registered in Prospero (CRD42023360259). PubMed, Embase, Web of Science, IEEE Xplore, and <strong>Cochrane Central Register of Controlled Trials</strong> (CENTRAL) databases and the European Centre for Disease Prevention and Control (ECDC) websites were searched for publications reporting on cases of <em>Aedes</em>-borne infection in Europe between January 1st, 2000, and December 31st, 2023.</div></div><div><h3>Results</h3><div>Some 353 papers were included, covering 59,589 cases of infection in Europe by seven arboviruses: dengue, Zika, chikungunya, yellow fever, Mayaro, Ross River, and Rift Valley. Most cases (55,924) were travel related, while 5 % were autochthonous. There were 59 cases of non-vector-borne transmission, primarily Zika-related sexual transmissions. Nineteen deaths were reported, of which three were associated with chikungunya virus infection, 12 with dengue, and four with yellow fever. Notable sequelae included persistent arthralgia from chikungunya and neurological effects in Zika-infected infants. The meta-analysis of 31 studies revealed a pooled prevalence of 0.047 (95 % CI: 0.03–0.07) in symptomatic returning travelers.</div></div><div><h3>Conclusion</h3><div>The systematic review provides a comprehensive overview of over 20 years of <em>Aedes</em> -borne infections in Europe, highlighting the dynamic nature of virus transmission influenced by global travel patterns, climate change, the expanding spread of <em>Aedes</em> populations, and evolving public health campaigns.</div></div>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"64 ","pages":"Article 102799"},"PeriodicalIF":6.3,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Costs of typhoid vaccination for international travelers from the United States","authors":"Heesoo Joo ,&nbsp;Brian A. Maskery ,&nbsp;Louise K. Francois Watkins ,&nbsp;Joohyun Park ,&nbsp;Kristina M. Angelo ,&nbsp;Eric S. Halsey","doi":"10.1016/j.tmaid.2025.102798","DOIUrl":"10.1016/j.tmaid.2025.102798","url":null,"abstract":"<div><div>In the United States, typhoid vaccination is recommended for international travelers to areas with a recognized risk of typhoid exposure. Using MarketScan® Commercial Database from 2016 through 2022, we estimated typhoid vaccination costs by route (injectable vs. oral) and provider setting (clinic vs. pharmacy). Of 165,930 vaccinated individuals, 99,471 received injectable and 66,459 received oral typhoid vaccines, with 88 % and 17 % respectively administered at clinics. Average costs for injectable vaccination were $132.91 per person [95 % confidence interval (CI): $132.68–$133.13], with clinic and pharmacy costs at $136.38 [95 % CI: $136.14–$136.63] and $107.45 [95 % CI: $107.13–$107.77], respectively. Oral vaccination costs averaged $81.23 per person [95 % CI: $81.14–$81.33], encompassing $86.61 [95 % CI: $86.13–$87.10] at clinics and $80.14 [95 % CI: $80.09–$80.19] at pharmacies. Out-of-pocket costs comprised 21 % and 33 % of total costs for injectable and oral vaccinations. These findings may inform clinical decision-making to protect international travelers’ health.</div></div>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"64 ","pages":"Article 102798"},"PeriodicalIF":6.3,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case report of pediatric scrub typhus presenting as acalculous cholecystitis during the non-epidemic season without eschar","authors":"Ruonan Li ,&nbsp;Yanchun Wang ,&nbsp;Xiaotao Yang ,&nbsp;Yonghan Luo","doi":"10.1016/j.tmaid.2025.102797","DOIUrl":"10.1016/j.tmaid.2025.102797","url":null,"abstract":"","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"64 ","pages":"Article 102797"},"PeriodicalIF":6.3,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142966691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 2023 dengue outbreak in Lombardy, Italy: A one-health perspective","authors":"Francesca Rovida ,&nbsp;Marino Faccini ,&nbsp;Carla Molina Granè ,&nbsp;Irene Cassaniti ,&nbsp;Sabrina Senatore ,&nbsp;Eva Rossetti ,&nbsp;Giuditta Scardina ,&nbsp;Manuela Piazza ,&nbsp;Giulia Campanini ,&nbsp;Daniele Lilleri ,&nbsp;Stefania Paolucci ,&nbsp;Guglielmo Ferrari ,&nbsp;Antonio Piralla ,&nbsp;Francesco Defilippo ,&nbsp;Davide Lelli ,&nbsp;Ana Moreno ,&nbsp;Luigi Vezzosi ,&nbsp;Federica Attanasi ,&nbsp;Marzia Soresini ,&nbsp;Manuela Barozzi ,&nbsp;Enrico Tallarita","doi":"10.1016/j.tmaid.2025.102795","DOIUrl":"10.1016/j.tmaid.2025.102795","url":null,"abstract":"<div><h3>Introduction</h3><div>Here we reported the virological, entomological and epidemiological characteristics of the large autochthonous outbreak of dengue (DENV) occurred in a small village of the Lombardy region (Northern Italy) during summer 2023.</div></div><div><h3>Methods</h3><div>After the diagnosis of the first autochthonous case on August 18, 2023, public health measures, including epidemiological investigation and vector control measures, were carried out. A serological screening for DENV antibodies detection was offered to the population. In the case of positive DENV IgM, a second sample was collected to detect DENV RNA and verify seroconversion. Entomological and epidemiological investigations were also performed. A modeling analysis was conducted to estimate the dengue generation time, transmission potential, distance of transmission, and assess diagnostic delays.</div></div><div><h3>Results</h3><div>Overall, 416 subjects participated to the screening program and 20 were identified as DENV-1 cases (15 confirmed and 5 probable). In addition, DENV-1 infection was diagnosed in 24 symptomatic subjects referred to the local Emergency Room Department for suggestive symptoms and 1 case was identified through blood donation screening. The average generation time was estimated to be 18.3 days (95 % CI: 13.1–23.5 days). R₀ was estimated at 1.31 (95 % CI: 0.76–1.98); 90 % of transmission occurred within 500m. Entomological investigations performed in 46 pools of mosquitoes revealed the presence of only one positive pool for DENV-1.</div></div><div><h3>Discussion</h3><div>This report highlights the importance of synergic surveillance, including virological, entomological and public health measures to control the spread of arboviral infections.</div></div>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"64 ","pages":"Article 102795"},"PeriodicalIF":6.3,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Icterus provoked by Echinococcus mimicking a tumor: A diagnostic challenge","authors":"Bojan Miletic ,&nbsp;Yves Sutter ,&nbsp;Elefteri Buset ,&nbsp;Silvije Segulja ,&nbsp;Marcus Hesse","doi":"10.1016/j.tmaid.2024.102790","DOIUrl":"10.1016/j.tmaid.2024.102790","url":null,"abstract":"","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"63 ","pages":"Article 102790"},"PeriodicalIF":6.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) in combination with rabies vaccination in Chinese healthy adults: A phase Ib randomized, double-blind, parallel-controlled clinical study","authors":"Yin Yin ,&nbsp;Min Jia ,&nbsp;Yufeng Li ,&nbsp;Wei Zhao ,&nbsp;Shuhong Chen ,&nbsp;Peiyuan Huo ,&nbsp;Qinghua Zhao ,&nbsp;Lan Yu ,&nbsp;Cha Wang ,&nbsp;Yirui Ma ,&nbsp;Meixia Wang ,&nbsp;Jing Zhang","doi":"10.1016/j.tmaid.2024.102792","DOIUrl":"10.1016/j.tmaid.2024.102792","url":null,"abstract":"<div><h3>Background</h3><div>The combination of passive immune agents (human rabies immune globulin (HRIG) and equine rabies antiserum (ERA)) with vaccines are effective measures for preventing the onset of rabies post exposure. However, ERA and HRIG have potential risks of serum allergic reactions and blood-transmitted infectious diseases. This study compared the safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) and HRIG in combination with rabies vaccine and vaccine alone.</div></div><div><h3>Method</h3><div>This randomized, double-blind, parallel-controlled Phase Ib clinical study was conducted in healthy Chinese population to evaluate the safety, pharmacokinetics, and neutralizing activity of rhRIG at dosages of 20IU/kg and 40IU/kg in combination with vaccines, and to compare the neutralizing activity of rhRIG + vaccine with that of HRIG + vaccine and vaccine alone. 72 healthy participants divided into 6 groups of 12 individuals.</div></div><div><h3>Results</h3><div>The rhRIG at dosages of 20IU/kg and 40IU/kg in combination with vaccines showed favorable safety and presented the pharmacokinetic property of linear elimination. The antibody neutralizing activity of rhRIG has the same level as HRIG in combination with vaccines. The rhRIG did not affect the long-term protective effect of the vaccine.</div></div><div><h3>Conclusions</h3><div>The rhRIG could provide immediate immune protection at the wound site and producing earlier protection during the window period before the rabies vaccine established active immunity. Therefore, it is recommended to continue to evaluate the safety and antibody neutralizing activity of rhRIG (20 and 40IU/kg) in combination with the vaccine in Phase II clinical trials.</div></div><div><h3>Trials registration</h3><div>ChiCTR1900023785 (<span><span>https://www.chictr.org.cn</span><svg><path></path></svg></span>).</div></div>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"63 ","pages":"Article 102792"},"PeriodicalIF":6.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The leading “blended” civil medical evacuation operation (MEDEVAC) in unforeseen health emergency. From military use to civil development","authors":"Nazzareno Fagoni ,&nbsp;Giuseppe Stirparo ,&nbsp;Giuseppe Maria Sechi ,&nbsp;Andrea Comelli ,&nbsp;Gabriele Perotti ,&nbsp;Guido Francesco Villa ,&nbsp;Alberto Zoli ,&nbsp;Marco Botteri","doi":"10.1016/j.tmaid.2024.102794","DOIUrl":"10.1016/j.tmaid.2024.102794","url":null,"abstract":"<div><h3>Introduction</h3><div>Medical evacuation has historically been rooted in military contexts. It involves the systematic transfer of sick or injured individuals from the battlefield to designated medical facilities. Medical evacuation has found application in civilian settings: the Ebola outbreak and the COVID-19 pandemic. This paper examines the medical evacuation that occurred during the COVID-19 pandemic in Lombardy, Italy (Operation “MEDEVAC”), where overloaded hospitals required the transfer of patients to other regions and even internationally.</div></div><div><h3>Methods</h3><div>MEDEVAC was implemented by the Regional Emergency and Urgency Agency (AREU). Data from MEDEVAC were analysed using the AREU register, detailing patient characteristics, transfer logistics, and outcomes.</div></div><div><h3>Results</h3><div>From March to April 2020, 121 intensive care patients were transferred via MEDEVAC, primarily by air. 65 % of patients were moved to other Italian regions. The Federal Republic of Germany received 35 % of patients, all transported by air. Outcome and mortality rates among transferred patients were comparable to those within regional intensive care units. One life-threatening event was reported during transport. The return of patient to Lombardy showed a 100 % survival rate.</div></div><div><h3>Conclusion</h3><div>This study emphasises the importance of standardised protocols, improved information exchange systems, and enhanced training for medical personnel involved in medical evacuation. MEDEVAC was found to be feasible and able to cope with demands that were excessive in relation to available resources. This study proposes the development of a shared protocol for air transport of patients and a model for international cooperation among emergency response agencies to optimise future medical evacuation activities in civil context.</div></div>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"63 ","pages":"Article 102794"},"PeriodicalIF":6.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143130035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Demographic, epidemiological and clinical characteristics of Ukrainian war refugees with HIV infection in the Slovak Republic” [Travel Med Infect Dis 62 (2024) 102764]","authors":"Ricardo Massmann ,&nbsp;Kristína Doležalová (Mgr) ,&nbsp;Lubomír Soják ,&nbsp;Olena Samsonová ,&nbsp;Danica Valkovičová Staneková ,&nbsp;Ondrej Zahornacký ,&nbsp;Pavol Jarčuška ,&nbsp;Mária Záriš Vachalíková ,&nbsp;Diana Vološinová ,&nbsp;Ľubica Piesecká ,&nbsp;Veronika Vahalová ,&nbsp;Katarína Šimeková ,&nbsp;Terézia Smiešková ,&nbsp;Alexandra Bražinová ,&nbsp;Ivy Kigen ,&nbsp;Marek Malý ,&nbsp;Ladislav Machala","doi":"10.1016/j.tmaid.2024.102791","DOIUrl":"10.1016/j.tmaid.2024.102791","url":null,"abstract":"","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"63 ","pages":"Article 102791"},"PeriodicalIF":6.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between influenza vaccination and prognosis in patients with ischemic heart disease: A systematic review and meta-analysis of randomized controlled trials","authors":"Xiao Liu ,&nbsp;Jiayu Zhang ,&nbsp;Fuwei Liu ,&nbsp;Yifan Wu ,&nbsp;Lin Li ,&nbsp;Ruoyun Fan ,&nbsp;Changchang Fang ,&nbsp;Jinyi Huang ,&nbsp;Deju Zhang ,&nbsp;Peng Yu ,&nbsp;Huilei Zhao","doi":"10.1016/j.tmaid.2024.102793","DOIUrl":"10.1016/j.tmaid.2024.102793","url":null,"abstract":"<div><h3>Background</h3><div>There is substantial epidemiological evidence demonstrating that influenza contributes to cardiovascular events in patients who already have cardiovascular diseases. However, the efficacy of influenza vaccination on the prognosis of patients with ischemic heart disease (IHD) is unclear.</div></div><div><h3>Methods</h3><div>We conducted a systematic search for eligible randomized controlled trials (RCTs) in PubMed, Cochrane, and Embase on September 13, 2024, to investigate the effects of the influenza vaccine on the prognosis of patients with IHD. The effect sizes were combined using random-effects models, and Trial Sequential Analysis (TSA) was used to assess the reliability and validity of the results.</div></div><div><h3>Results</h3><div>Five RCTs with a total of 5659 patients (median age ranging from 57.1 to 66 years, 67.8% male) with IHD were included. The use of influenza vaccine reduced the risk of major adverse cardiovascular events (risk ratio [RR] = 0.67, 95% confidence interval [CI] 0.52–0.87, number-needed-to-treat [NNT] of 37, high certainty), cardiovascular death (RR = 0.55, 95% CI 0.35–0.87, moderate certainty), all-cause mortality (RR = 0.58, 95% CI 0.40–0.84, high certainty) and myocardial infarction (MI) (RR = 0.66, 95% CI 0.46–0.93, high certainty) in patients with IHD compared with control. The analysis revealed no significant benefit regarding hospitalization for heart failure (HF) (RR = 0.91, 95% CI 0.21–3.99, moderate certainty) and revascularization (RR = 0.59, 95% CI 0.10–3.45, moderate certainty). The NNT to avoid 1 event was 37 for major adverse cardiovascular events, 56 for cardiovascular death, 67 for MI, and 41 for all-cause death. TSA showed that the benefit of influenza vaccine in reducing MACE was conclusive, no more trials were necessary.</div></div><div><h3>Conclusion</h3><div>This study suggests high level of evidence that the use of influenza vaccine reduce the risk of major adverse cardiovascular events in patients with IHD.</div></div>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"64 ","pages":"Article 102793"},"PeriodicalIF":6.3,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}